FDA Cleared Ixempra Despite Doubts Over Chance Of Showing Survival Benefit
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Doubts about the likelihood that the improvement in progression-free survival seen in a pivotal trial of Bristol-Myers Squibb's Ixempra (ixabepilone) will translate to an overall survival advantage could add to the controversy over the appropriateness of PFS as a surrogate for survival in metastatic breast cancer.
You may also be interested in...
Ixempra Bar Graphs Land Bristol-Myers Sales Aid In The Slammer
FDA notice of violation letter to the company says its promotion material, which relies heavily on subgroup analyses of secondary endpoints, makes unsubstantiated efficacy claims and broadens the indication for the breast cancer drug.
Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy
Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.
Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy
Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.